{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-037770","form_type":"8-K","ticker":"AIDX","cik":"0001139685","company_name":"20/20 Biolabs, Inc.","filed_at":"2026-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.001733+00:00","generated_at":"2026-05-15T07:56:37.429076+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"20/20 BioLabs FY 2025 revenue $2.0M (+17%); gross margin expands; $5M private placement","bullets":["Revenue $2.0M (+17% YoY); gross profit $0.6M (+68%); gross margin 29.6% vs 20.6%.","Operating expenses down 35% to $3.9M; net loss improved 33% to ($3.7)M; cash $1.0M.","Completed $5.0M private placement Feb 2026; up to $40M available in tranches.","MDH awarded $520K to 18 fire departments for OneTest MCED; Medicare MCED pathway law signed Feb 2026.","Launched OneTest for Longevity with IBM AI; exclusive license with ROKIT Healthcare for CKD prediction."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-037770","json":"https://secwatch.observer/filing/0001213900-26-037770.json","markdown":"https://secwatch.observer/filing/0001213900-26-037770.md","text":"https://secwatch.observer/filing/0001213900-26-037770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026037770/0001213900-26-037770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026037770/ea028443201-8k_2020bio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:56:37.429076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b3c1a9949e2c559ae2767680333f15a26167408c","claim":"20/20 Biolabs, Inc. reported the full year ended December 31, 2025 results: revenue $2.0 million, net income ($3.7) million.","evidence_excerpt":"Revenue of $2.0 million for FY 2025, representing an increase of 17% over FY 2024. ● Deferred revenue totaled approximately $0.4 million as of December 31, 2025. ● Gross profit of $0.6 million for FY 2025, representing an increase of 68% over FY 2024. Gross margin was 29.6% in FY 2025, compared to 20.6% in FY 2024. ● Total operating expenses decreased 35% to $3.9 million in FY 2025 compared to $6.0 million in FY 2024. ● FY 2025 net loss improved 33% to ($3.7) million, compared to ($5.6) million in FY 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026037770/0001213900-26-037770-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Revenue","value":"$2.0 million"},{"label":"Net income","value":"($3.7) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}